BioNexus Gene Lab

BioNexus Gene Lab EBIT per Share

The EBIT per Share of BioNexus Gene Lab (BGLC) as of Oct 29, 2026 is -1.31 USD. In the previous year, EBIT per Share was -0.88 USD — a change of 49.18% (lower).

EBIT per Share

-1.31USD

YoY

49.18%

Last updated:

EBIT per Share of BioNexus Gene Lab is 2025 -1.31 USD. EBIT per Share of BioNexus Gene Lab was 2024 -0.88 USD. It decreases by 49.18% lower compared to the previous year.

The BioNexus Gene Lab EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2018
0.11 USD
Jan 1, 2019
-0.32 USD
Jan 1, 2020
1.48 USD
Jan 1, 2021
0.01 USD
Jan 1, 2022
-0.02 USD
Jan 1, 2023
-1.47 USD
Jan 1, 2024
-0.88 USD
Jan 1, 2025
-1.31 USD
The BioNexus Gene Lab EBIT per Share history
YEAREBIT per ShareYoY
-1.31USD+49.18%
-0.88USD-40.32%
-1.47USD+7,196.64%
-0.02USD-426.17%
0.01USD-99.58%
1.48USD-567.17%
-0.32USD-378.06%
0.11USD-139.48%
-0.29USD+82,784.82%
-0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioNexus Gene Lab Stock analysis

What does BioNexus Gene Lab do? BioNexus Gene Lab Corp. develops and markets non-invasive blood tests for early disease detection, analyzing RNA changes to assess risks for over 11 diseases. The company’s subsidiary, Bionexus Gene Lab Sdn. Bdh., supports these operations. Products are sold to healthcare providers and diagnostic centers seeking advanced, non-invasive testing solutions. The firm targets medical professionals and institutions focused on personalized health management through functional genomics applications. The company generates revenue through the sale of its RNA-based blood tests, which are marketed as tools for early disease risk assessment. Healthcare institutions and diagnostic service providers purchase these tests to enhance their diagnostic capabilities. The focus on non-invasive methods aligns with growing demand for patient-friendly diagnostic technologies in the molecular diagnostics sector. BioNexus Gene Lab Corp. operates with a small team of 5 full-time employees, emphasizing efficiency in product development and marketing. The subsidiary Bionexus Gene Lab Sdn. Bdh. facilitates local operations, though specific market segments are not detailed beyond healthcare providers and diagnostic centers. Revenue streams are derived solely from test sales, with no mention of additional services or partnerships. BioNexus Gene Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioNexus Gene Lab stock

EBIT per Share of BioNexus Gene Lab is -1.31 USD in 2025.

EBIT per Share of BioNexus Gene Lab changed from -0.88 USD to -1.31 USD, representing a 49.18% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share BioNexus Gene Lab since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — BioNexus Gene Lab

All Key Metrics — BioNexus Gene Lab